New gel treatment aims to reduce 'Off' episodes in Parkinson's
NCT ID NCT07313176
First seen Jan 03, 2026 · Last updated May 22, 2026 · Updated 23 times
Summary
This study follows 215 adults with advanced Parkinson's disease who are switching from a subcutaneous medication to LECIGON, an intestinal gel. Researchers will measure how much the gel reduces daily 'OFF' time (when symptoms return) over 12 months. The goal is to better control motor fluctuations, not to cure the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED PARKINSON DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Complejo Hospitalario Universitario de A Coruña (CHUAC)
RECRUITINGA Coruña, 15006, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Virgen del Rocío University Hospital
RECRUITINGSeville, Av. Manuel Siurot, S/n, 41013, Spain
Contact
Conditions
Explore the condition pages connected to this study.